Allergan, an AbbVie Company (NYSE:ABBV), and clinical-stage biotechnology company Molecular Partners (SIX:MOLN) reported on Thursday that that the US Food and Drug Administration (FDA) has issued a Complete Response Letter to the Biologics License Application (BLA) for Abicipar pegol, a novel, investigational DARPin therapy for patients with neovascular (wet) age-related macular degeneration (nAMD).
In the CRL, the FDA indicates that the rate of intraocular inflammation observed following administration of Abicipar pegol 2mg/0.05 ml results in an unfavorable benefit-risk ratio in the treatment of nAMD.
AbbVie intends to meet with the FDA to discuss its comments and determine next steps.
DARPin molecules are derived from naturally occurring binding proteins that consist of repeat sequences with capping structures at each end of the protein. They have three key properties that have made them an important investigational class of binding protein for researchers: high binding affinity, low molecular weight and customizable applications.
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
BD receives FDA clearance for Surgiphor 1000mL irrigation system
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study
FDA accepts rusfertide NDA and grants priority review for polycythemia vera